Compare HALO & DPZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HALO | DPZ |
|---|---|---|
| Founded | 1998 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Food Distributors |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.2B |
| IPO Year | 2001 | 2004 |
| Metric | HALO | DPZ |
|---|---|---|
| Price | $125.99 | $312.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 30 |
| Target Price | $108.78 | ★ $356.48 |
| AVG Volume (30 Days) | ★ 2.2M | 805.1K |
| Earning Date | 11-05-2026 | 10-13-2026 |
| Dividend Yield | N/A | ★ 2.51% |
| EPS Growth | N/A | ★ 5.27 |
| EPS | 3.11 | ★ 12.80 |
| Revenue | $151,862,000.00 | ★ $4,939,994,000.00 |
| Revenue This Year | $34.69 | $4.99 |
| Revenue Next Year | $11.65 | $1.70 |
| P/E Ratio | $39.88 | ★ $24.79 |
| Revenue Growth | N/A | ★ 4.96 |
| 52 Week Low | $61.23 | $282.00 |
| 52 Week High | $125.43 | $442.35 |
| Indicator | HALO | DPZ |
|---|---|---|
| Relative Strength Index (RSI) | 74.21 | 53.32 |
| Support Level | $105.27 | $297.56 |
| Resistance Level | N/A | $320.57 |
| Average True Range (ATR) | 3.51 | 9.34 |
| MACD | 1.11 | 2.63 |
| Stochastic Oscillator | 99.04 | 85.23 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Domino's is the world's largest pizza chain, surpassing $20 billion in system sales with over 22,100 stores across more than 90 markets at the end of 2025. Around 33% of its units are in the US. The business is 99% franchised. Domino's operates through three segments: supply chain (60% of revenue), US stores (33%), and international franchises (7%). The firm generates the bulk of its revenue by supplying food to stores in the US and Canada through a vertically integrated network of 25 manufacturing and supply chain facilities, which primarily produce and distribute dough, and by collecting brand royalties and marketing fees from franchisees. Domino's also generates revenue from sales at company-owned stores.